Fusion of Clinical and Deep Learning Features for Predicting Pembrolizumab Monotherapy Response in Advanced Non-Small Cell Lung Cancer

Liton Devnath, Ian Janzen, Cheryl Ho, Barbara Melosky, Stephen Lam, Calum MacAulay, Ren Yuan · 2026

Read Fusion of Clinical and Deep Learning Features for Predicting Pembrolizumab Monotherapy Response in Advanced Non-Small Cell Lung Cancer by Liton Devnath, Ian Janzen, Cheryl Ho, Barbara Melosky, Stephen Lam, Calum MacAulay, Ren Yuan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13300846.txt.

Description

Liton Devnath and co-authors combine deep learning image features with clinical data to predict who will not respond to pembrolizumab alone in advanced lung cancer, in a 2026 study. Over half of patients with high PD-L1 expression still fail this first-line immunotherapy, so early warning would speed a switch to other treatment. The retrospective cohort held ninety-seven patients for training and seventeen for a preliminary test, with responses judged from follow-up scans.

From 128 image features, the team ranked the ten most discriminative and paired them with five clinical descriptors in a support vector machine. That blend reached the best balance on the small test set, catching most non-responders while keeping false alarms moderate. Performance looked stronger inside the training data, a gap the authors openly note. They present the fused model as a promising decision aid that needs bigger validation cohorts.

Catalog record

CREATORLiton Devnath, Ian Janzen, Cheryl Ho, Barbara Melosky, Stephen Lam, Calum MacAulay, Ren Yuan
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13300846

Browse the full library · About the Tower of Babel